Dr Rob Scott is Zimbabwean born and a graduate of University of Cape Town. Rob has held leadership positions in global Pharma for over thirty years. At Pfizer he developed Lipitor and Norvasc, including personal involvement in many large scale CV trials. At AtheroGenics, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. At Amgen, Rob conducted the first outcome study for a PCSK9i, FOURIER. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016. Rob is currently the Chief Medical Officer at Abbvie with responsibility for around 40 new molecular entities, four thousand people and a budget of close to three billion dollars. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics and big data to design and implementing clinical trials. He is a board member of Transcelerate and a member of the PhRMA R&D Leadership Forum. Rob is a leader in digital transformation of clinical research.

Eddie Power PhD MBA is currently the VP, North America Medical Affairs, Hospital Business at Pfizer and has held positions of increasing responsibility during his career in the pharmaceutical industry.

He started at Pfizer in September 2010 leading US teams in Vaccines and Infectious Diseases before assuming before assuming US Medical Affairs leadership for Pfizer’s Essential Health business Unit. Before joining Pfizer, Eddie held Medical and Clinical Development positions at Cubist, Bayer and GSK.

He has a passionate interest in learning and capability development for Medical Affairs colleagues and teaches for the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy/Kings College Medicines Development Certification Program.

Before joining the pharmaceutical industry, Eddie held a faculty position at United Medical and Dental Schools, Guy’s & St Thomas’ Hospitals, London, UK. He holds a PhD degree from the Welsh School of Pharmacy, University of Wales, UK and an MBA from Henley Management College, UK

Dan Atlan, MD, is currently working in global medical affairs (GMA) in Servier. Dan is passionate in Medical Affairs over 16 years, typically cross functional leadership, launch preparation activities and set up of new structures or team integration following acquisitions. In 2016, he set up the first GMA team in this company starting with Oncology area and has set up the first GMA cross TA excellence unit. Previously, Dan worked in Novartis oncology and Janssen for various roles in medical affairs, from local to global positions, specifically in oncology. Originally, Dan is a clinical oncologist, trained in France and has practiced in academic hospitals over a decade.

A British national with a clinical pharmacology degree from the University of Manchester (UK), an MPhil in Neuroscience from Cardiff University (UK), and PhD in Neuroscience/Neuropharmacology from the Georg-August-University Gottingen (Germany) together with the University Medical Centre Goettingen, and Max-Planck institutes for experimental medicine and Biophysical Chemistry, working on the topics of movement disorders, myelin research, human stem cell research for Parkinson’s, and models of Alzheimer’s disease. Afterwards a post-doctorate was obtained in Pharmacology from the Max-Planck Institute for Heart and Lung Research Bad Nauheim (Germany) working on orphan GPCRs.                                                                                                                    Initially, I worked in ICON a clinical research organization, later entering the consumer/FMCG industry as medical marketing manager for L’Oreal Germany, leading medical consumer marketing initiatives in dermatology and nutrition (with Nestle) across Germany, Austria and Switzerland. Later, joining the pharmaceutical industry as international associate medical director for Gruenenthal Pharmaceuticals, managing products in chronic pain across EU+ regions. Afterwards, I made the move to rare diseases and worked at Shire Pharmaceuticals in Switzerland as global associate director of medical communications for genetic diseases (Fabry and Gaucher disease), and HAE. My current position is Global Medical Director and therapeutic area head of CNS & Pain at Abbott across the emerging markets and responsible for all pipeline and mature product programs. Amongst other things, my passion is neuroscience and improving global mental health.

John-Kenneth holds a medical degree from the University of Antwerp in Belgium where he also obtained a MBA degree.

He has been working in the Bio-pharmaceutical industry since 1993 in various roles with a country, European and global perspective leading large virtual teams, driving organizational change processes and being involved directly in 5 major launches. He has been Medical Director in Belgium, the Netherlands and the UK, was global medical affairs franchise lead and afterwards European medical affairs Neurology lead at UCB, before joining Merck KGaA in January 2017. 

John-Kenneth is passionate for translating scientific data into patient solutions through intensive collaboration with both internal and external stakeholders. As a former patient himself he experienced the importance of innovation, communication, transparency and collaboration between stakeholders to optimize individual patient outcomes. 

I have a 34 year diverse career in the pharmaceutical industry.  I received my Doctorate of Pharmacy degree from Rutgers University. I started my career at Lerderle Labs (Pearl River, NY) cross-training in various roles including Quality Control/Validation Specialist, Sr. Formulations Researcher, Sr. Chemistry, Manufacturing & Control (CMC) Regulatory Affairs Manager and Production Supervisor leading 25 Union Operators in Manufacturing & Production.  After my diverse 10 year career with Lederle, I broadened my experience working at  Warner Lambert/Parke Davis as a Senior Clinical Research Associate and subsequently joined Schering Plough as Sr. Manager, Regulatory Affairs.  I joined Allergan in 2002 increasing my depth and breadth of experience as a Medical Science Liaison (MSL), Sr. MSL, East Region MSL Peer Leader, National Director, Neuroscience MSL Team (2013) and most recently Director, Global Medical Excellence since 2016.

Over the last 24 years, Eric has gained fundamental life science and pharmaceutical industry experience covering Drug Development, Medical Affairs, Alliance Management and External Innovation.

Eric started his pharmaceutical career back in 1996 in France before moving to the UK in 1997 at a time where the EMA established itself at Canary Wharf and the Bristish biotech business was booming.

From clinical research management to global cross-functional drug development leadership, he has led many early stage to life cycle management product development in a variety of therapeutic areas such as oncology, gastro-enterology, bone health, inflammation, CNS, neurosciences.

Opportunities took him through a range of companies from virtual biotechs (SR Pharma, spinoff from UCL) to small & mid-size pharmaceutical entities (Norgine, Ipsen), to larger organisations such as Amgen.

Although Eric takes pride of being capable to “kill products quickly” as they appear not to be able to deliver the promise of the 4 hurdles (safety, efficacy, quality, access), Eric also achieved to deliver products to the market as he led the successful registration, approval and launch of 3 Biological License Applications in the US and equivalent in European/Worldwide markets…this being for adult and paediatric populations. To Eric, the ability to help and serve patients including children, providing them with beneficial treatment solutions and some relief to their debilitating condition is the most rewarding achievement.

With that strong track record, Eric embarked in an executive role at Ipsen Global Medical Affairs, reporting to the CMO, building the infrastructures & capabilities, as well as overseeing its execution.

More recently, Eric joined Accord Healthcare as Associated VP, Scientific Affairs – Operations, where he provides medical affairs leadership to the portfolio’s strategy and operational execution in the EMENA region.

Severin Fürhapter holds a master’s degree in Physics obtained at the University of Innsbruck, and a PhD in Medical Sciences from the Innsbruck Medical University. He started his career as Scientific Research Assistant at Innsbruck Medical University in 2004. In 2008, he joined Vibrant MED-EL’s Clinical Support and gained profound clinical expertise in supporting medical devices throughout their lifecycle. Severin was promoted to the Head of Hearing Science in 2011, focusing on health technology assessment and reimbursement activities. Since 2013 he is Head of Hearing Science and Clinical Research at MED-EL, Business Unit Vibrant. His responsibilities cover all aspects of Clinical Research, Health Technology Assessment and Applied Hearing Science, looking both on clinical parameters of several product lines and their reimbursement in a cross-functional department.

With 20 plus years of progressive leadership in academia, biotech, and consulting, Elisabeth has led the Medical Affairs function at Voyager Therapeutics, Inc since its inception. She brings to her current role a track record of building cross-functional, long-term, patient-focused strategies in Medical Affairs and Communications and the operational infrastructure to support their successful implementation. Throughout her biotech career she has developed deep experience in Medical Affairs strategy and tactics, Commercial and payer communications, and Regulatory Affairs, and has launched drugs in the US, EU, and around the world, supporting Medical Affairs, Regulatory Affairs, and Commercial. Elisabeth is a Visions Scientist by training, and prior to joining biotech was on the faculty of the Schepens Eye Research Institute/Harvard Medical School.

Dr Kieran Breen is currently Head of Research and Development at St Andrew’s Healthcare which is a secure mental health facility with accommodation for over 850 patients. He has expertise in the development of multi-disciplinary research initiatives including the establishment and utilisation of patient clinical data registries. In collaboration with the US Critical Path Institute, he established a Parkinson’s Disease data registry initiative involving participants from academia, industry, regulatory bodies and patient groups. He is a member of the European Medicines Agency Committee for Advanced Therapies where he also serves on the cross-Committee working group on patient data registries. As a member of the EMA Patients and Consumers Working Party, he has liaised closely with the public on the use of clinical data in the development of clinical trials and post marketing medicines monitoring.

Alex Wyke is CEO and founder of PatientView, a UK-based research, publishing and consultancy group. PatientView has worked to build bridges worldwide with the health NGOs that comprise the patient movement, to help define and support one of the most important phenomenon changing healthcare in the 21st Century. (For more on PatientView, see: www.patient-view.com). PatientView is the publisher and owner of the series Corporate Reputation of Pharma – from a patient perspective, Benchmarking the patient Movement as well as the online mhealth resource for public and patients, myhealthapps.net.

From 1996 to 2000 Alex was responsible for creating and running the international healthcare publishing unit at The Economist Intelligence Unit. She was previously business and science correspondent for The Economist.

I've only been at NICE for 6 months, but prior to that I worked at the University of Manchester for 10 years, primarily with the Trauma Audit & Research Network - a group that collects real world data about patients that have suffered from severe trauma in the UK and Ireland. There I gained extensive experience in assessing the quality of and gaining insights from real world data.

Hari is a customer engineer at Google Cloud with a focus on Life Sciences, genomics and Biotech. He spent more than fifteen years in technology roles helping customers drive value from data across Pharmaceutical, Healthcare, Biotech and other sectors before joining Google Cloud.  At Google, he is focused on making Cloud and ML accessible to enterprises, start-ups, and researchers, to drive innovation and growth.

Andy is a healthcare communications specialist with over 30 years of experience within the global pharmaceutical and biotechnology sectors and has the responsibility of leading the partnership efforts for Within3 in Europe.

Andy started his pharmaceutical career as a medical representative in the UK with Glaxo, progressing within the industry through training, sales management and marketing before leaving the client side of the business to take up senior roles in advertising, PR, sales promotion, direct marketing, clinical research, medical education and communications.

Throughout his career Andy has been passionate about strengthening the bond between the patient and the HCP and as a consequence he has worked extensively with patients, PAGs and medical societies in Parkinson’s disease, HIV and AIDS, Crohn’s Disease, Diabetes, transplantation and COPD. Most recently Andy has been working in ankylosing spondylitis and psoriatic arthritis to help accelerate the patient journey towards effective treatment and improving the dialogue between the patient and physician.

Andy is a certified medical publications professional (CMPP) and a Practitioner at the Association for Business Psychology

An experienced senior executive with several years of experience in the Pharmaceutical & Biotechnology industry, Dr. Soliman has held key positions where he was instrumental in launching a variety of innovative platforms in medical affairs. He speaks frequently regarding the ever changing role of medical affairs at major medical affairs conferences. He currently the Executive Chair, President on the board of the Accreditation Council for Medical Affairs (ACMA) whose primary mission is to create industry standards and goals for medical affairs professionals.

He has held several management roles across the industry within medical affairs such as at Retrophin, Eisai, Gilead Sciences, Abbott Laboratories, Boehringer-Ingelheim, and Merck.  Dr. Soliman previously also served as Vice President of Medical & Scientific Affairs at CME LLC, a leading provider of CME to health care providers nationwide. He also has worked on the strategic management consulting side with companies such as Veeva systems, and is often brought in as a subject matter expert on medical affairs for healthcare investment and advisory firms. 

He has published extensively & led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity where he has collaborated with some of the nation's top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program and the University of Pennsylvania's Center for Weight & Eating Disorders.  Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also recently presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among pre-diabetic overweight and obese individuals. In 2008, Dr. Soliman published a book entitled The Rise of Chemistry: Implications for Industry & Education. 

Dr. Soliman is featured in the media and news often for his perspective and views on the evolving role of medical affairs/MSLs in the pharmaceutical industry. He has been featured in Forbes, the Pharmaceutical Executive, ABC News, the Pharmacy Podcast, and most recently on Relentless Health Value with well-known host Stacey Richter who focused on healthcare thought leaders. 

He has also held several academic appointments at Seton Hall University's School of Health & Medical Sciences, New Jersey City University, Kean University's College of Natural & Applied Sciences, and Touro Colleges of Osteopathic Medicine, Pharmacy & Physical Therapy teaching a variety of courses including clinical therapeutics, pharmacology, pathophysiology, and epidemiology. 

Dr. Soliman earned his PhD, MPhil from Columbia University, his Bachelor’s degree from New York University and a Masters Degree from St. Peter's University. He completed post-doctoral training at Harvard University’s T.H Chan School of Public Health. 

Amanda Pulfer is Joint Managing Director at pH and manages the team of RWE consultants responsible for the design of robust Real World Evidence solutions to meet the needs of our pharmaceutical industry clients and NHS collaborators.  Amanda has more than 10 years’ experience in RWE consultancy and works with clients to develop robust 3-5 year RWE plans to support their portfolios through interactive facilitated workshops. Prior to joining pH Associates Amanda worked in the pharmaceutical industry for more than 10 years’ in a variety of roles in sales and marketing.  She brings to pH first-hand experience of the challenges faced by pharmaceutical companies and an understanding of the complexity involved in overcoming these whilst meeting NHS needs.  Amanda has a degree in Natural Sciences from Cambridge University (Part II Molecular Cell Biology) and completed a postgraduate Diploma in Marketing from the Chartered Institute of Marketing

Tessa graduated with a degree and professional diploma in Strategic Marketing in the early 1990s. Her formative years were spent in client facing roles at advertising agencies, including Saatchi and Saatchi and FCB in London, where she looked after Financial Services and FMCG clients. Tessa launched PharmaReview 7 years ago, with Dr Ralph Carter.  PharmaReview is a   specialist provider of outsourced copy review services to the pharmaceutical industry.  Its  mission is to reduce the time and cost which internal copy review places on senior members of  clients’ medical, regulatory and commercial teams while maintaining the highest levels  of regulatory adherence and compliance. Tessa is a highly experienced practitioner in ZincMAPS and Veeva Vault PromotMats functionaility and a copy review process expert.

Jeremy A. Rassen, MS, ScD is a pharmacoepidemiologist with 25 years of academic and industry experience.  He is co-founder, president, and chief science officer at Aetion, a health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. He also worked in Silicon Valley in a variety of tech companies.  Dr. Rassen received his bachelor’s degree in Computer Science from Harvard College and his master’s and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.

Jeremy A. Rassen, MS, ScD is co-founder, president, and chief science officer at Aetion, a health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. He also worked in Silicon Valley in a variety of tech companies.  Dr. Rassen received his bachelor’s degree in Computer Science from Harvard College and his master’s and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.

Dr Paul Tunnah founded pharmaphorum in 2009, which combines industry leading

publications (www.pharmaphorum.com) with a specialist strategy and content communications / marketing consultancy (www.pharmaphorumconnect.com). All aspects of his work at pharmaphorum align around the company’s vision of ‘bringing healthcare together’ – ensuring all stakeholders have a voice and can collectively engage to find mutually beneficial solutions.

He is a recognised author, speaker and industry advisor on content marketing, communications and digital innovation, having worked with many of the world’s leading pharmaceutical companies and the broader ecosystem of healthcare organisations. He is also a member of the steering committee for Frontiers Health, a leading event on digital disruption in healthcare, attended by industry, start-ups and investors.

Dr Tunnah has a scientific background, with a BA in Biochemistry and DPhil in Biological sciences, focussed on development of novel anticancer therapies, from Oxford University.

Connect with Dr Tunnah at https://www.linkedin.com/in/paultunnah/ or email paul.tunnah@pharmaphorum.com.